{
    "id": "8dfaa874-d6cf-4107-b57f-25dab02aa201",
    "indications": "carefully consider potential benefits risks diclofenac potassium tablets treatment options deciding diclofenac potassium tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . diclofenac potassium tablets indicated : •for treatment primary dysmenorrhea •for relief mild moderate pain •for relief signs symptoms osteoarthritis •for relief signs symptoms rheumatoid arthritis",
    "contraindications": "carefully consider potential benefits risks diclofenac potassium immediate-release tablets treatment options deciding diclofenac potassium tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . observing response initial therapy diclofenac potassium tablets , dose frequency adjusted suit individual patient ’ needs . treatment pain primary dysmenorrhea recommended 50 mg three times day . experience , physicians may find patients initial dose 100 mg diclofenac potassium tablets , followed 50-mg doses , provide better relief . relief osteoarthritis recommended 100 150 mg/day divided doses , 50 mg twice day three times day . relief rheumatoid arthritis recommended 150 200 mg/day divided doses , 50 mg three times day four times day . different formulations diclofenac [ voltaren® ( diclofenac sodium enteric-coated tablets ) ; voltaren®-xr ( diclofenac sodium extended-release tablets ) ; diclofenac potassium tablets ] necessarily bioequivalent even milligram strength .",
    "warningsAndPrecautions": "diclofenac potassium tablets usp , 50 mg available orange , round , biconvex , film-coated tablets debossed numbers “ 93 ” “ 948 ” one face tablet plain . bottles 30 ndc 68788-8411-3 bottles 60 ndc 68788-8411-6 bottles 90 ndc 68788-8411-9 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect moisture . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . brands listed trademarks respective owners . dispense medication guide available : www.tevausa.com/medguides manufactured israel : teva pharmaceutical ind . ltd. kfar saba , 4410202 , israel manufactured : teva pharmaceuticals parsippany , nj 07054 rev . r 12/2024 repackaged : preferred pharmaceuticals inc .",
    "adverseReactions": "diclofenac contraindicated following patients : •known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ) . •history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ) . •in setting coronary artery bypass graft ( cabg ) surgery ( ) .",
    "ingredients": [
        {
            "name": "DICLOFENAC POTASSIUM",
            "code": "L4D5UA6CB4"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "INDIGOTINDISULFONATE SODIUM",
            "code": "D3741U8K7L"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIBASIC CALCIUM PHOSPHATE",
            "code": "91D9GV0Z28"
        }
    ],
    "organization": "Preferred Pharmaceuticals Inc.",
    "name": "Diclofenac Potassium",
    "effectiveTime": "20250430",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ).\n                  Diclofenac potassium tablets are indicated:\n                  \n                     \n                        •for treatment of primary dysmenorrhea\n                     \n                        •for relief of mild to moderate pain\n                     \n                        •for relief of the signs and symptoms of osteoarthritis\n                     \n                        •for relief of the signs and symptoms of rheumatoid arthritis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see  ). \n                  After observing the response to initial therapy with diclofenac potassium tablets, the dose and frequency should be adjusted to suit an individual patient’s needs. \n                  For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg three times a day. With experience, physicians may find that in some patients an initial dose of 100 mg of diclofenac potassium tablets, followed by 50-mg doses, will provide better relief. \n                  For the relief of osteoarthritis the recommended dosage is 100 to 150 mg/day in divided doses, 50 mg twice a day or three times a day. \n                  For the relief of rheumatoid arthritis the recommended dosage is 150 to 200 mg/day in divided doses, 50 mg three times a day or four times a day. \n                  Different formulations of diclofenac [VOLTAREN® (diclofenac sodium enteric-coated tablets); Voltaren®-XR (diclofenac sodium extended-release tablets); diclofenac potassium tablets] are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac potassium tablets USP, 50 mg are available as orange, round, biconvex, film-coated tablets debossed with the numbers “93” and “948” on one face of the tablet and plain on the other.\n                  Bottles of 30 NDC 68788-8411-3\n                  Bottles of 60 NDC 68788-8411-6\n                  Bottles of 90 NDC 68788-8411-9\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Brands listed are the trademarks of their respective owners.\n                  Dispense with Medication Guide available at: www.tevausa.com/medguides\n                  Manufactured In Israel By:\n                     Teva Pharmaceutical Ind. Ltd.\n                     Kfar Saba, 4410202, Israel\n                  Manufactured For:\n                     Teva Pharmaceuticals\n                     Parsippany, NJ 07054\n                   Rev. R 12/2024\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions_original": "Diclofenac is contraindicated in the following patients:\n                  \n                     \n                        •Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see ). \n                     \n                        •History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see ). \n                     \n                        •In the setting of coronary artery bypass graft (CABG) surgery (see  )."
}